Latest Neurodegenerative disease Stories
University of Tennessee molecular biophysics professor reveals a key trigger to a rare but deadly neurodegenerative diseaseJeremy Smith, Governor's Chair for Molecular Biophysics at the University of Tennessee, Knoxville, has helped reveal a key trigger of Gerstmann"“Sträussler"“Scheinker (GSS) syndrome, a rare but deadly neurodegenerative disease. The finding could have far-reaching implications for the treatment of other neurodegenerative diseases such as Alzheimer's, Huntington's,...
An international research team, co-led by scientists at Mayo Clinic's campus in Florida, have discovered three potential susceptibility genes for development of progressive supranuclear palsy (PSP), a rare neurodegenerative disease that causes symptoms similar to those of Parkinson's disease but is resistant to Parkinson's medications. Their report is being published online June 19 in Nature Genetics.The findings provide a "testable translational hypothesis" as to the development...
Initial step towards early identification and treatment of progressive supranuclear palsyThere are new genetic clues on risk factors and biological causes of a rare neurodegenerative disease called progressive supranuclear palsy (PSP), according to a new study from an international genetics team led by researchers from the Perelman School of Medicine at the University of Pennsylvania. In the largest genetics study of the disease, three new genes associated with risk for PSP were identified...
TIMONIUM, Md., June 19, 2011 /PRNewswire/ -- An international team of researchers led by Gerard D. Schellenberg, PhD, a member of the CurePSP Genetics Consortium and professor of Pathology and Laboratory Medicine in the Perelman School of Medicine at the University of Pennsylvania, has identified three new genes that can increase the risk of people developing Progressive Supranuclear Palsy (PSP). To view the multimedia assets associated with this release, please click:...
NEW YORK, June 15, 2011 /PRNewswire-USNewswire/ -- The Alzheimer's Drug Discovery Foundation (ADDF) and The Association for Frontotemporal Degeneration (AFTD) invite scientists from academia and the biotechnology industry worldwide to apply for research grants to develop Frontotemporal Dementia (FTD)-specific biomarkers that reflect pathological and clinical differences so that appropriate patients can be selected for clinical trials and responses to investigational treatments can be...
MONTREAL, June 14, 2011 /PRNewswire/ - Immunotec Inc. (TSXV: IMM) (www.immunotec.com/IRL/Public/en/CAN/science_research.wcp) announces that data from research using Immunocal® in a mouse model by Principal Investigator Daniel Linseman, PhD and his team at the University of Denver in Colorado shows promise in delaying the onset of amyotrophic lateral sclerosis. Investigators studied mice harbouring the gene that is responsible for some forms of the disease commonly known as ALS...
( Ivanhoe Newswire) -- Huntington's disease is a devastating inherited neurogenetive disorder that is fatal. The disorder affects the central nervous system by causing progressive degeneration of cells in the brain, slowly impairing a person's ability to walk, think, talk, and reason. Now, researchers may have uncovered a novel approach to treat this incurable disease.Huntington's disease can either be early or adult-onset, adult being the most common usually developed in a person's mid 30s...
Research offers new hope for key neurodegenerative disordersScientists at the Gladstone Institutes have identified a drug candidate that diminishes the effects of both Alzheimer's disease and Huntington's disease in animal models, offering new hope for patients who currently lack any medications to halt the progression of these two debilitating illnesses.Gladstone Investigator Paul Muchowski, PhD, has identified a new compound called JM6 in experiments done in collaboration with an...
New research offers promise of medical intervention for this devastating disorderMedical researchers may have uncovered a novel approach to treat an incurable and ultimately fatal neurodegenerative disease that affects hundreds of thousands of people.Two international studies, one led by the University of Leicester, and the other a collaboration with Leicester led by scientists in the USA, hold out promise for slowing down the development of Huntington's disease "“ and potentially,...
A drug already approved for people with cancer shows early potential as a therapy for a common form of dementia, UT Southwestern Medical Center researchers report."Suberoylanilide hydroxamic acid (SAHA) holds promise as a first-generation drug for the prevention and treatment of familial frontotemporal dementia (FTD), a progressive, inherited neurodegenerative disease for which there is no treatment," said Dr. Joachim Herz, director of the Center for Alzheimer's and...
